Mineralys Therapeutics (MLYS) Share-based Compensation (2022 - 2026)

Mineralys Therapeutics has disclosed Share-based Compensation across 5 years of filings, most recently posting $6.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $6.5 million, up 79.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.2 million (up 73.78% YoY), and the FY2025 annual result was $19.3 million, up 70.47% from the prior year.
• Share-based Compensation came in at $6.5 million for Q1 2026 at Mineralys Therapeutics, up from $5.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.5 million in Q1 2026 to a low of $19000.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $2.2 million (2024), against an average of $2.5 million.
• Across the five-year window, Share-based Compensation surged 4807.69% in 2023 and soared 58.53% in 2025, its largest moves.
• Mineralys Therapeutics' Share-based Compensation stood at $218000.0 in 2022, then jumped by 568.35% to $1.5 million in 2023, then surged by 115.1% to $3.1 million in 2024, then jumped by 68.63% to $5.3 million in 2025, then advanced by 23.9% to $6.5 million in 2026.
• The last three Share-based Compensation figures came in at $6.5 million (Q1 2026), $5.3 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.